1887

Abstract

T cell-mediated cytotoxicity may play an important role in controlling infection by human immunodeficiency virus (HIV). In order to study the ability of rationally designed antigens to induce cytolytic T lymphocytes (CTLs) we replaced stretches of 30 to 50 amino acids at the p17-MA/p24-CA cleavage site, within the p24-CA moiety and within the p6-LI portion of the HIV type 1 p55 precursor by the third variable domain (V3) of the external glycoprotein gp120. This site is known to be a target for CTL attack in mice and humans. The chimeric antigens were recombined into highly attenuated vaccinia viruses in order to investigate class I major histocompatibility complex (MHC)-restricted presentation of antigenic V3 peptides. Immunoprecipitation and Western blot analysis of the group-specific antigen (p55)/V3 chimeric proteins demonstrated significant differences in the accessibility of the V3 domain for a monoclonal antibody or polyclonal V3-specific antisera, depending on the position of the V3 loop within the p55 carrier protein. Immunization of BALB/c mice with three variants of p55/V3 recombinant vaccinia virus, however, resulted in a comparable priming of CD4 CD8 CTLs irrelevant of the position of the V3 loop within p55. Local conformational changes, including the V3 domain within the p55/V3 chimeras, did not demonstrate a significant effect on V3-specific lysis of the target cells when compared to the authentic gp120 envelope protein. Class I MHC-restricted CTLs induced by a V3 consensus sequence cross-reacted perfectly with the LAI strain-derived V3 loop sequence. These data indicate that the combination of selected epitopes (V3) with immunologically relevant complex carrier proteins (p55) can be accomplished without the loss of biological activity.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-74-7-1261
1993-07-01
2021-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/74/7/JV0740071261.html?itemId=/content/journal/jgv/10.1099/0022-1317-74-7-1261&mimeType=html&fmt=ahah

References

  1. Beesley KM, Francis MJ, Clarke BE, Beesley IE, Dopping-Heppenstal PJ, Clare JJ, Brown F, Romanos MA. 1990; Expression in yeast of amino-terminal peptide fusions to hepatitis B core protein antigen and their immunological properties. Bio/Technology 8:644–649
    [Google Scholar]
  2. Berman PW, Gregory TJ, Riddle L, Nakamura MA, Champe MA, Porter JP, Wurm FM, Hersberg RD, Cobb EK, Eichberg JW. 1990; Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature, London 345:622–625
    [Google Scholar]
  3. Bjork RL. 1991; HIV-1: seven facets of functional molecular mimicry. Immunology Letters 28:91–95
    [Google Scholar]
  4. Buseyne F, McChesney M, Porrot F, Kovarik S, Guy B, Riviere Y. 1993; Gag-specific T-lymphocytes from human immunodeficiency virus type 1-infected individuals: gag epitopes are clustered in three regions of the p24gag protein. Journal of Virology 67:694–702
    [Google Scholar]
  5. Ceredig R, Lowenthal JW, Nabholz M, MacDonald HR. 1985; Expression of 11-2 receptors as a differentiation marker in intrathymic stem cells. Nature, London 314:98–100
    [Google Scholar]
  6. Chakrabarti S, Robert-Guroff M, Wong-Staal F, Gallo RC, Moss B. 1986; Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature, London 320:535–538
    [Google Scholar]
  7. Clerici M, Lucey DR, Zajac RA, Boswell RN, Gebel HM, Takahashi H, Berzofsky JA, Shearer GM. 1991; Detection of cytotoxic T-lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. Journal of Immunology 146:2214–2219
    [Google Scholar]
  8. Del Val M, Schlicht H.-J, Ruppert T, Reddehase MJ, Koszinowski UH. 1991; Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66:1145–1153
    [Google Scholar]
  9. Devash Y, Calvelli TA, Wood DG, Reagan KJ, Rubinstein A. 1990; Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proceedings of the National Academy of Sciences, U.S.A. 87:3445–3449
    [Google Scholar]
  10. Emini EA, Nara PL, Schleif WA, Lewis JA, Da vide JP, Lee DR, Kessler J, Conley S, Matsushita S, Putney SD, Gerety RJ, Eichberg JW. 1990; Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. Journal of Virology 64:3674–3678
    [Google Scholar]
  11. Girard M, Kieny M.-P, Pinter A, Barre-Sinoussi F, Nara P, Kolbe H, Kusumi K, Chaput A, Reinhart T, Muchmore E, Ronco J, Kaczorek M, Gomard E, Gluckman J.-C, Fultz PN. 1991; Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy of Sciences, U.S.A. 88:542–546
    [Google Scholar]
  12. Golding H, Robey FA, Gates FT. 1988; Identification of homologous regions in HIV-1 gp41 and human MHC class II domain. Journal of Experimental Medicine 167:914–918
    [Google Scholar]
  13. Golding H, Shearer GM, Hillman K, Lucas K, Manis-chewitz J, Zajac RA, Clerici M, Gress RE, Boswell NR, Golding B. 1989; Common epitope in HIV-1 gp41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV infected individuals. Journal of Clinical Investigation 83:1430–1435
    [Google Scholar]
  14. Göttlinger HE, Sodroski JG, Haseltine WA. 1989; Role of the capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences, U.S.A. 86:5781–5785
    [Google Scholar]
  15. Goudsmit J, Debouch C, Meloen RH, Smit L, Barker M, Asher DM, Wolff AV, Gibbs CJ, Jr, Gajdusek DC. 1988; Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proceedings of the National Academy of Sciences, U.S.A. 85:4478–4482
    [Google Scholar]
  16. Hahn YS, Braciale VL, Braciale TJ. 1991; Presentation of viral antigen to class I MHC-related cytolytic T-lymphocyte. Recognition of an immunodominant influenza hemagglutinin site by cytolytic T-lymphocyte is independent of the position of the site in the hemagglutinin translation product. Journal of Experimental Medicine 174:733–736
    [Google Scholar]
  17. Hart MK, Weinhold KJ, Scearce RM, Washburn EM, Clark CA, Palker TJ, Haynes BF. 1991; Priming of antihuman immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Medical Sciences 88:9448–9452
    [Google Scholar]
  18. Kingsman SM, Adams SE, Kingsman AJ. 1989; The yeast retrotransposon Ty: molecular genetics and exploitation. Bio/Technology 13:145–163
    [Google Scholar]
  19. König S, Fürst TR, Wood LV, Woods RM, Suzich JA, de la Cruz VF, Davay RT, Jr, Venkatesan S, Moss B, Biddison WE, Fauci AS. 1990; Mapping the fine specificity of a cytolytic T-cell response to HIV nef protein. Journal of Immunology 145:127–135
    [Google Scholar]
  20. Lasky L, Nakamura G, Smith DH, Fennie C, Shimasaki C, Patzer E, Bermann P, Gregory P, Capon D. 1987; Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50:975–985
    [Google Scholar]
  21. Mackett M, Smith GL, Moss B. 1984; General method for production and selection of infectious vaccinia virus recombinants expressing recombinant foreign genes. Journal of Virology 49:857–864
    [Google Scholar]
  22. Maddon PJ, Dalgleish AG, McDougal IS, Clapham PR, Weiss RA, Axel R. 1986; The T4 gene encloses the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47:333–348
    [Google Scholar]
  23. Modrow S, Hahn BH, Shaw GM, Gallo RC, Wong-Staal F, Wolf H. 1987; Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. Journal of Virology 61:570–578
    [Google Scholar]
  24. Modrow S, Höflacher B, Mellert W, Erfle V, Wahren B, Wolf H. 1989; Use of synthetic oligopeptides in identification and characterization of immunological functions in the amino acid sequence of the envelope protein of HIV-1. Journal of Acquired Immune Deficiency Syndromes 2:21–27
    [Google Scholar]
  25. Nixon DF, Townsend ARM, Elvin JG, Rizza CR, Gallwey J, McMichael AJ. 1988; HIV-1 gag-specific cytotoxic T-lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature, London 336:484–487
    [Google Scholar]
  26. Palker TJ, Clark ME, Langlois AJ, Matthews TJ, Weinhold KJ, Randall RR, Bolognesi DP, Haynes BF. 1988; Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proceedings of the National Academy of Sciences, U.S.A. 85:3198–3202
    [Google Scholar]
  27. Papsidero LD, Sheu M, Ruscetti FW. 1989; Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p 17 core protein: characterization and epitope mapping. Journal of Virology 63:267–272
    [Google Scholar]
  28. Phillips RE, Rowland-Jones S, Nixon D, Gotch FM, Edwards JP, Ogunlesi AO, Elvin J, Rothbard JA, Bangham CRM, Rizza CR, McMichael A. 1991; Human immunodeficiency virus genetic variation that escape cytotoxic T-cell recognition. Nature, London 354:453–459
    [Google Scholar]
  29. Robinson WE, Jr, Montefiori DC, Mitchell WM, Prince AM, Alter HJ, Dreesman GR, Eichberg JW. 1989; Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1 infected and passively immunized chimpanzees. Proceedings of the National Academy of Sciences, U.S.A. 86:4710–4714
    [Google Scholar]
  30. Robinson WE, Jr, Kawamura T, Gorny MK, Lake D, Xu JY, Matsumoto Y, Sugano T, Masuho Y, Mitchell WM, Hersh E, Zola-Pazner S. 1990; Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proceedings of the National Academy of Sciences, U.S.A. 87:3185–3189
    [Google Scholar]
  31. Rusche FR, Javaherian K, McDanal C, Petro J, Lynn DL, Grimaila R, Langlois A, Gallo RC, Arthur LO, Fischinger PJ, Bolognesi DP, Putney SD, Matthews TJ. 1988; Antibodies that inhibit fusion of HIV-infected cells bind a 24 amino acid sequence of the viral envelope, gp120. Proceedings of the National Academy of Sciences, U.S.A. 85:3198–3202
    [Google Scholar]
  32. Sambrook J, Fritsch EF, Maniatis T. 1989 Molecular Cloning: A Laboratory Manual, 2nd edn. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  33. Sarmiento M, Glasebrook AL, Fitch FW. 1980; IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt2 antigen block T cell-mediated cytolysis in the absence of complement. Journal of Immunology 125:2665–2672
    [Google Scholar]
  34. Schlienger K, Manchini M, Riviere Y, Dormont D, Tiollais P, Michel MD. 1992; Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates. Virology 66:2570–2576
    [Google Scholar]
  35. Shirai M, Pendleton CD, Berzowski JA. 1992; Broad recognition of cytolytic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. Journal of Immunology 148:1657–1667
    [Google Scholar]
  36. Siliciano RF, Trebor L, Knall C, Karr RW, Berman P, Gregory T, Reinherz EL. 1988; Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion. Cell 54:561–575
    [Google Scholar]
  37. Takahashi H, Cohen J, Hosmalin A, Crase KB, Houghten R, Cornette J, Delisi C, Moss B, Germain RN, Berzofsky JA. 1988; An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp120 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T-lymphocytes. Proceedings of the National Academy of Sciences, U.S.A. 85:3105–3109
    [Google Scholar]
  38. Takahashi H, Houghten R, Putney SD, Margulies DH, Moss B, Germain RN, Berzofsky JA. 1989; Structural requirements for class I MHC molecule mediated antigen presentation and cytolytic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein. Journal of Experimental Medicine 170:2023–2035
    [Google Scholar]
  39. Takahashi H, Houghten R, Putney SD, Margulies DH, Moss B, Germain RN, Berzofsky JA. 1990a; Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein. Journal of Experimental Medicine 170:2023–2035
    [Google Scholar]
  40. Takahashi H, Merli S, Putney SD, Houghten R, Moss B, Germain RN, Berzofsky JA. 1990b; A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. Science 246:118–121
    [Google Scholar]
  41. Takahashi H, Nakawaga Y, Pendleton CD, Houghten RA, Yocomuro K, Germain RN, Berzofsky JA. 1992; Induction of broadly cross-reactive cytolytic T cells recognizing an HIV-1 envelope determinant. Science 225:335–336
    [Google Scholar]
  42. Takeda A, Tuazon CU, Ennis FA. 1988; Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242:580–583
    [Google Scholar]
  43. Townsend AR. M, Bastin J, Gould K, Brownlee GG. 1986; Cytolytic T-lymphocytes recognize and influence hemagglutinin that lacks a signal sequence. Nature, London 324:575–575
    [Google Scholar]
  44. Townsend ARM, Bastin J, Gould K, Brownlee GG, Andrew M, Coupar B, Boyle D, Chan S, Smith G. 1988; Defective presentation to class 1 restricted cytotoxic T-lymphocytes in vaccinia infected cells is overcome by enhanced degradation of the antigen. Journal of Experimental Medicine 168:1211–1224
    [Google Scholar]
  45. Tsubota H, Lord CL, Watkins DL, Morimoto C, Letvin NL. 1989; A cytotoxic T-lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. Journal of Experimental Medicine 169:1421–1434
    [Google Scholar]
  46. von Brunn A, Früh K, Müller HM, Zentgraf HW, Bujard H. 1991; Epitopes of the human malaria parasite P. falciparum carried on the surface of HBsAg particles elicit an immune response against the parasite. Vaccine 9:477–501
    [Google Scholar]
  47. von Poblotzki A, Wagner R, Niedrig M, Wanner G, Wolf H, Modrow S. 1993; Identification of a region in the Pr55gag polyprotein essential for HIV-1 particle formation. Virology (in press).
    [Google Scholar]
  48. Wagner A, FlieBbach H, Modrow S, von Brunn A, Wolf H, Boltz T, Gelderblom H. 1991; Expression of autologous p55 and p55/gp120-V3 core particles: a new approach in HIV vaccine development. In Vaccines 91. Modern Approaches to New Vaccines Including Prevention of AID pp 109–114Edited by Chanock RM, Ginsberg HS, Brown F, Lerner RA. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  49. Wagner R, FlieBbach H, Wanner G, Motz M, Niedrig M, Deby G, von Brunn A, Wolf H. 1992a; Studies on processing, particle formation and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Archives of Virology 127:117–137
    [Google Scholar]
  50. Wagner R, Modrow S, Boltz T, FlieBbach H, Niedrig M, von Brunn A, Wolf H. 1992b; Immunological reactivity of a human immunodeficiency virus type 1-derived peptide representing a consensus sequence of the gp120 major neutralizing region V3. Archives of Virology 12:139–152
    [Google Scholar]
  51. Walker BD, Chakrabarti S, Moss B. 1987; HIV-specific cytotoxic T-lymphocytes in seropositive individuals. Nature, London 328:325–348
    [Google Scholar]
  52. Walker CM, Moody DJ, Stites DP, Levy JA. 1989; CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563–1566
    [Google Scholar]
  53. Weinhold KJ, Lyerly HK, Stanley SD, Austin AA, Matthews TJ, Bolognesi DP. 1989; HIV-1 gp120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. Journal of Immunology 142:3091–3092
    [Google Scholar]
  54. Wolf H, Modrow S, Soutschek E, Motz M, Grunow R, Dobl H. 1990; Production, mapping and biological characterization of monoclonal antibodies to the core protein (p24) of the human immunodeficiency virus type 1. AIDS-Forschung 1:24–29
    [Google Scholar]
  55. Young JAT. 1988; HIV and HLA similarity. Nature, London 333:215–215
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-74-7-1261
Loading
/content/journal/jgv/10.1099/0022-1317-74-7-1261
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error